Abstract | OBJECTIVE: METHODS: RESULTS: The 75 study patients (46 women and 29 men with a mean age of 56.4 years) were admitted for nerve root pain, osteoporotic vertebral fracture, inflammatory joint disease, or other disorders. First-line treatment was sustained-release morphine sulfate in a mean starting dosage of 55.2 mg/day. The dosage was increased if needed (mean maximum dosage, 78.3 mg/day). Mean treatment duration was 8.9 days. Adverse effects were recorded in 73.3% of patients but were usually minor, requiring no change in the treatment regimen. Eight patients experienced serious adverse effects ( confusion in five and urinary retention in three) that resolved with no change in treatment in two patients, after dosage reduction in two patients and after substitution of fentanyl or hydromorphone hydrochloride in four patients. Treatment discontinuation was not associated with adverse effects. CONCLUSIONS:
Morphine is often responsible for adverse effects in patients with acute nonmalignant musculoskeletal pain. These effects are usually moderate and very rarely require discontinuation of the drug.
|
Authors | Anne Cherasse, Géraldine Muller, Paul Ornetti, Christine Piroth, Christian Tavernier, Jean Francis Maillefert |
Journal | Joint bone spine
(Joint Bone Spine)
Vol. 71
Issue 6
Pg. 572-6
(Nov 2004)
ISSN: 1297-319X [Print] France |
PMID | 15589442
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Analgesics, Opioid
- Morphine
|
Topics |
- Acute Disease
- Adult
- Aged
- Analgesics, Opioid
(administration & dosage, adverse effects)
- Female
- Hospitalization
- Humans
- Male
- Middle Aged
- Morphine
(administration & dosage, adverse effects)
- Musculoskeletal Diseases
(complications)
- Pain
(drug therapy, etiology)
- Prospective Studies
- Treatment Outcome
|